Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness

Mm. Hi everyone, I'm Nikola Tanyan, the CEO of the Norwegian Sovereign Wealth Fund, and today I'm in really good company with Vas. Narasiam, the CEO of Novartis. Voss has one of the most fascinating backgrounds in a pharma. He is a trained physician. Who also worked on the front lines fighting tuberculosis and malaria in developing countries, before rising to lead one of the world largest pharmaceutic companies. We own two point three percent of Novartis, and that's worth More than five billion dollars. Roughly ten thousand Norwegian croner.

current Norwegian citizen. So Voss, big thanks for joining us. Great to be here, Nikola. Just uh briefly to uh kick off. For those who are not familiar with novartists, just uh what are your areas of focus? Yeah, we're one of the largest biopharmaceutical companies uh in the world focused on innovative medicines and oncology.

uh cardiovascular disease, neuroscience, and an immunological diseases. Very good. And we'll come back to uh to many of those. Um now you have a different background uh compared to many other pharma CEOs. How do you think that has shaped your approach to approach to leading noveltis? Well I think it's uh it's helped in many dimensions. I mean being coming from f uh being a physician Coming from a scientific background. I'm definitely steeped in the R and D elements of the work we do. So I'm always thinking about the medicine, how the medicines impact patients.

We already have this episode, so unlocking it is cheap and permanent: the full transcript (47 minutes, 8,931 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.

No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.